title: Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.
authors.affiliation: Department of Internal Medicine (Division of Oncology) and Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA.
authors.forename: Zachary
authors.initials: Z
authors.lastname: Reese
authors.forename: Shiven
authors.initials: S
authors.lastname: Patel
authors.forename: David D
authors.initials: DD
authors.lastname: Stenehjem
authors.forename: Ignacio
authors.initials: I
authors.lastname: Garrido-Laguna
mesh_terms: D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine